Analysts await Cytosorbents Corporation (NASDAQ:CTSO) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.1 EPS, up 10% or $0.01 from last year’s $-0.11 per share.

At the moment 5 analysts are watching Cytosorbents Corporation (NASDAQ:CTSO), 2 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 2.01 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 2.42 million whilst for the year ending Dec-16, 2 analysts have a mean target of 8.44 million.

In terms of earnings per share, 3 analysts have a -0.09 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 3 analysts have a -0.09 EPS mean target and for the quarter ending Sep-16 there are 3 estimates of -0.38 EPS.

The biggest institutional shareholders in Cytosorbents Corporation include Vanguard Group Inc which owns 508 K million shares in the company valued at $2.83 million. PineBridge Investments LLC is the second biggest holder with 240 K million shares currently valued at 1.34 million whilst Geode Capital Management, LLC has 126 K million shares valued at 701.00 K million.

Total shares held by institutions as of the most recent company filings are 1,314,000 with a reported 60,227 bought and 26,498 sold. These holdings make up 5.17% of the company’s outstanding shares.

Currently insiders hold 18,037,650 shares in the business which makes up 71.00% of shares. The biggest holder currently is David Lamadrid who owns 7,837,500 shares (30.85% of those outstanding), whilst Montiel Guillermina holds 4,993,984 (19.66% of shares outstanding) and Margie Chassman holds 4,795,000 (18.87% of shares outstanding).

The stock increased 0.46% or $0.02 during the last trading session, hitting $5.65. Cytosorbents Corporation (NASDAQ:CTSO) has fallen 41.59% over the past 6 months and is downtrending.